Acino

We provide quality medicines in high-growth markets and leverage our manufacturing capabilities and network to supply leading pharma companies.

[Acino @AcinoSwiss]

Arcera has acquired exclusive rights from AriBio to commercialize an investigational oral therapy for early-stage Alzheimer’s disease in Latin America, the Middle East, Southern Africa, Ukraine and select Eurasian countries.

Read more: https://t.co/fC0SfrjrT4

#CNS #Alzheimer

[Acino @AcinoSwiss]

Acino South Africa is officially a #TopEmployer for the 4th year in a row! This certification from @topemployer highlights our efforts to achieve excellence in people practices and makes us very proud.

💼 Ready to accelerate your career? https://t.co/irlpI8FmMg

#WeAreAcino

[Acino @AcinoSwiss]

As we reflect on the past year, we are grateful for the trust and collaboration of our partners, colleagues and friends.

May this holiday season bring you and your loved ones joy, peace and prosperity. We look forward to achieving even greater milestones together next year.

[Acino @AcinoSwiss]

We are excited to announce a transformative new chapter for Acino as we align under the #OneArcera umbrella to drive sustainable growth and innovation in life sciences.

Read more here: https://t.co/I6EKqR4cuX

#LifeSciences #SustainableGrowth #TogetherWeThrive

[Acino @AcinoSwiss]

🎧 Tune in to #CPHI Milan's @ThePharmaSource podcast for insights from our COO, @NashartySamir, on how we are setting the standard for supply chain excellence to bring proven and innovative medicines to patients in emerging markets.

#Pharma #Operations #techOps #Manufacturing

[PharmaSource @ThePharmaSource]

How Acino Manages 90 CMOs Across Emerging Markets: A Masterclass in Supply Chain Resilience https://t.co/ezacJLufgL

[Acino @AcinoSwiss]

🎥 Watch the interview of Rafael Ferrer, our Interim Chief Business Officer, who shares insights into Acino's efforts to expand patient access to quality healthcare in emerging markets and delves into the evolving landscape of pharma.

https://t.co/ei4Mzr36FC

[Acino @AcinoSwiss]

Acino publishes second annual Sustainability Report, underscoring our continued commitment to Environmental, Social, and Governance (ESG) goals.

More: https://t.co/xymsjngj8n

#Sustainability #ESG

[Acino @AcinoSwiss]

❤️ Happy World Heart Day!​ ❤️
​
At Acino, we believe that by working together, investing in #CVD prevention and innovation, we can create a world where heart health is a priority, and everyone has equal access to quality care.​
​
More: https://t.co/19OA8p0Hat
​
#WHD #WeAreAcino

[Acino @AcinoSwiss]

https://t.co/G60zIwgnUy

[Best Places to Work @BPTW4]

Congratulations to @AcinoSwiss #Iraq for achieving the #BestPlacestoWork certification in #Iraq for 2024! This remarkable achievement highlights @AcinoSwiss #Iraq ongoing dedication to excellence and making a positive impact in the healthcare industry. #BestPlaceSToWorkinIraq

[Acino @AcinoSwiss]

Let’s explore new healthcare frontiers at CPHI 8 - 10 October in Milan.

Join us at #CPHI to start your journey. Book your meeting now: https://t.co/EFb40o7nex

#CPHI2024 #Partnership #BuisinessOpportunites #LetsExplore

[Acino @AcinoSwiss]

We signed an exclusive licensing and distribution agreement with LG Chem Ltd., to market, commercialise, and distribute novel treatments for type 2 Diabetes and Osteoarthritis in Latin America.

More: https://t.co/VCOLu0Vgch

#PartnerWithAcino #Diabetes #Osteoarthritis

[Acino @AcinoSwiss]

We signed an exclusive agreement with Allecra Therapeutics to commercialize a novel antibiotic drug in South Africa and the GCC region, two key geographic regions for Acino.

More: https://t.co/FI363rhwj2

#Partnership #Infectiology

[Acino @AcinoSwiss]

We are excited to connect with visionary partners at #BIO2024. Acino's leaders Andrew Bird, CEO (ai), and Rafael Ferrer from Corporate Development will be in San Diego next week to explore partnership opportunities with biotech and pharma companies.
#PartnerWithAcino

[Acino @AcinoSwiss]

We have signed an exclusive licensing agreement with @Supernus_Pharma to introduce new products in Latin America for the treatment of attention deficit disorder (ADHD), strengthening our position in the #CNS therapeutic space.

More: https://t.co/M5bI7Qv8xu

#Pharma #Partnership

[Acino @AcinoSwiss]

Launch of our new hub in Latin America. Following the acquisition of M8, we are combining our businesses to drive pharmaceutical growth in the region and beyond. Joel Barlan appointed as Head of LATAM region.

Read more: https://t.co/TO48ljFiWL… #Pharma #LatinAmerica

[Acino @AcinoSwiss]

We are excited to enter the new phase of growth as part of the Arcera life sciences platform.

#LifeSciences #Arcera

Learn more: https://t.co/2nhlRYQrl5

[Acino @AcinoSwiss]

We are thrilled to announce Samir El Nasharty as our new Chief Operations Officer and member of Acino’s Executive Committee, starting 1st April, 2024. Samir brings invaluable skills and strategic insights to our team.

More: https://t.co/HfrtREvjdH

[Acino @AcinoSwiss]

We signed an exclusive agreement with SERB Pharmaceuticals to bring an important orphan drug for cancer patients in Latin America, which marks another step forward in our mission to advance healthcare in high-growth markets.

Read more: https://t.co/ZR2oeL7KT8

#Partnership

[Acino @AcinoSwiss]

Acino has appointed Ingrid Eberle as Chief Compliance and Sustainability officer. Looking to the future, we are proud to reaffirm Acino’s strategic commitment to environmental and social responsibility.

Read more: https://t.co/r0oFiE3cqx

#EthicalBusiness #SocialResponsibility

[Acino @AcinoSwiss]

Acino has signed an exclusive distribution agreement with Sobi for the commercialisation of several orphan drugs, marking a significant milestone in our commitment to healthcare innovation in Kazakhstan.

More: https://t.co/O9RFwR2qOH

#Partnership #RareDisease #Kazakhstan